RecruitingNCT06937996

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System


Sponsor

Englewood Hospital and Medical Center

Enrollment

25 participants

Start Date

May 13, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a procedure called irreversible electroporation (IRE), also known as NanoKnife, for treating locally advanced pancreatic cancer that cannot be removed by surgery. IRE uses electrical pulses to destroy tumor cells without damaging surrounding blood vessels or tissue. The study tracks outcomes in patients who have already received standard chemotherapy but whose cancer cannot be surgically removed. **You may be eligible if...** - You are 18 or older with locally advanced pancreatic cancer that cannot be removed surgically - You have already completed standard chemotherapy and possibly radiation - Your blood clotting levels are within safe range - You are willing to follow all study requirements **You may NOT be eligible if...** - Your kidney function is significantly impaired - You cannot stop blood-thinning medications before and after the procedure - You have a cardiac pacemaker or defibrillator - You have metal implants near the tumor area - You have a history of epilepsy or certain heart rhythm problems - You are pregnant or breastfeeding - You have a known allergy to contrast dye that cannot be managed medically Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENanoKnife

The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.


Locations(1)

Englewood Hospital

Englewood, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06937996


Related Trials